Volume 29, Number 7—July 2023
Research
Trajectory and Demographic Correlates of Antibodies to SARS-CoV-2 Nucleocapsid in Recently Infected Blood Donors, United States
James M. Haynes, Roger Y. Dodd, Lauren A. Crowder, Edward P. Notari, and Susan L. Stramer
Table 1
Cohort selection process for study of trajectory and demographic correlates of antibodies to SARS-CoV-2 nucleocapsid in recently infected blood donors, United States, June 2020‒June 2021*
| Characteristic |
No. donors (no. donations) |
|---|---|
| Donations received during June 2020‒June 2021 | 2,448,127 (5,221,553) |
| S1 reactive tested for N antibody | 1,092,736 (1,527,776) |
| N reactive | 321,387 (475,943) |
| Seroconverters, N antibody reactive after N antibody nonreactive | 54,414 (190,983) |
| Period to observed N antibody peak value <120 d from N antibody nonreactive | 32,376 (126,227) |
| Donations with N antibody signal value reported | 32,376 (89,682) |
| Observations at and after observed peak | 32,376 (61,432) |
| Donors with >1 observation after observed peak | 19,326 (48,382) |
| Observations that were valid or without apparent reinfection | 19,323 (48,330) |
*N, nucleocapsid; S, spike.
Page created: April 29, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.